Tandem Meetings 2023 | Clofarabine preconditioning followed by allogeneic transplantation with TBI & PTCy for R/R AML
Seema Naik, MD, Penn State Cancer Institute, Hershey, PA, comments on the results of a study investigating the efficacy and safety of clofarabine preconditioning for haploidentical transplantation with total body irradiation (TBI) and post-transplant cyclophosphamide (PTCy) for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr Naik explains that this strategy was well tolerated and will allow more patients to become eligible for stem cell transplantation (SCT). In addition, the study showed that using less TBI allowed reducing toxicity and graft-versus-host disease (GvHD) whilst achieving similar efficacy. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
